Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Updates Nilotinib CML Label With Discontinuation Provision

December 23rd 2017

The FDA has updated the label for nilotinib with a provision stipulating that patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have received the BCR-ABL tyrosine kinase inhibitor for at least 3 years and have achieved specific predetermined criteria may be eligible to stop treatment.

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017

Allogeneic Transplantation in Mantle Cell Lymphoma

December 23rd 2017

Acalabrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Ibrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Understanding Relapse in Mantle Cell Lymphoma

December 23rd 2017

Maintenance Therapy in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Autologous Stem Cell Transplantation

December 23rd 2017

Induction Therapy for Mantle Cell Lymphoma

December 23rd 2017

The Watch-and-Wait Approach in Mantle Cell Lymphoma

December 23rd 2017

The Value of MIPI and Ki-67 in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Diagnosing Mantle Cell Lymphoma

December 23rd 2017

Classifying Mantle Cell Lymphoma

December 23rd 2017

Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

December 22nd 2017

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.

Venetoclax Combo Reaches High CR Rate in Older AML Patients

December 20th 2017

Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.

Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up

December 20th 2017

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.

FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML

December 20th 2017

The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Selinexor Highly Active in Relapsed/Refractory AML

December 19th 2017

Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.